HealingImmune
LL-37
Cathelicidin peptide · 37 amino acids · Human-derived sequence
FDA · PRECLINICAL ONLY
Half-life
~30 minutes
Very short
minsdays
Route
SubQ injection
Evidence
Preclinical only
Risk
Standard
Overview
Known for
Mechanism
Key facts
Format
Lyophilized powder
Mechanism targets
Classification
Secondary
Supply & nature
Natural / Topping UpNatural
FDA category
Preclinical only
Evidence & standing
Evidence base
Preclinical only
Risk level
Standard
Best studies
5 references
Dosage & protocol
Typical dose
50-100mcg/day
Research range
1–5 mg
Cycle
4 weeks on / 4 weeks off
Onset
10 days first effects
Full effect
42 days
Half-life
~30min
~30 minutes to hours (rapidly degraded by proteases)
Protocol
Time to effects
Recommended vial
Reference figures only
Dosing reflects published laboratory protocols and is not guidance for use in any living subject.
Safety
Reversibility
Fully Reversible
Side effects
Interactions
Handle with research caution
Storage & handling
Lyophilised
12–24 months
2–8°C
Reconstituted
3–4 weeks
2–8°C
Videos & talks
Independent educational content from researchers, clinicians and science communicators — not affiliated with Pepnerd.
Educational resources only. Videos are independent third-party content. Pepnerd is not affiliated with these creators and does not endorse or make claims based on their content. All products are for in-vitro research.